Mrs Allison Chavanne, PT, DPT | |
32 W 19th Rd, Broad Channel, NY 11693-1212 | |
(917) 796-3643 | |
Not Available |
Full Name | Mrs Allison Chavanne |
---|---|
Gender | Female |
Speciality | Physical Therapist - Pediatrics |
Location | 32 W 19th Rd, Broad Channel, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821468166 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2251P0200X | Physical Therapist - Pediatrics | 027825 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Allison Chavanne, PT, DPT 32 W 19th Rd, Broad Channel, NY 11693-1212 Ph: (917) 796-3643 | Mrs Allison Chavanne, PT, DPT 32 W 19th Rd, Broad Channel, NY 11693-1212 Ph: (917) 796-3643 |
News Archive
Neuroscientists in Bonn and Heidelberg have succeeded in providing new insights into how the brain works. Researchers at the DZNE and the German Cancer Research Center analyzed tissue samples from mice to identify how two specific proteins, ‘CKAMP44' and ‘TARP Gamma-8', act upon the brain's memory center.
EKF Diagnostics, the global in vitro diagnostics company, announces it has secured new contracts for the manufacture and supply of a novel, patented sample collection device which allows COVID-19 samples to be rapidly inactivated in the collection tube, avoiding contamination and preserving RNA without need for refrigeration.
Grown like a snowflake and sharpened with a sewing machine, a novel device by Kansas State University researchers may benefit biomedical professionals and the patients they serve during electrode and organ transplant procedures.
Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.
Covance Inc. today announced the signing of definitive agreements with sanofi-aventis for Covance to become sanofi-aventis' R&D partner. Over the next ten years, Covance expects to provide drug development services to sanofi-aventis, with estimated payments ranging from approximately $1.2 billion to $2.2 billion.
› Verified 4 days ago